Abstract: The present disclosure relates to compounds of Formula (IA) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for the treatment of disorders in which P-glycoprotein and/or cytochrome P450 (e.g. CYP3A4) is modulated (e.g., cancers which have developed multi-drug resistance).
Type:
Grant
Filed:
October 7, 2021
Date of Patent:
August 29, 2023
Assignee:
Athenex, Inc.
Inventors:
Sameer Urgaonkar, Ahmed M. Said, Nader N. Nasief Abdel Sayed, Laura Beth Pitzonka, Murray John Cutler, Michael P. Smolinski, Johnson Yiu-Nam Lau
Abstract: The application relates to biaryl compounds, pharmaceutical compositions comprising the compounds, and methods of use the compounds for treating cell proliferation disorders.
Type:
Grant
Filed:
December 26, 2018
Date of Patent:
April 13, 2021
Assignee:
Athenex, Inc.
Inventors:
Michael P. Smolinski, Nader N. Nasief Abdel-Sayed, David G. Hangauer, Jr.
Abstract: The present application is directed to biaryl piperidine amide compounds, or pharmaceutically acceptable salts, solvates, and prodrugs thereof, and methods of use thereof.
Type:
Grant
Filed:
September 11, 2019
Date of Patent:
January 26, 2021
Assignee:
Athenex, Inc.
Inventors:
Michael P. Smolinski, Sameer Urgaonkar, James Lindsay Clements, David G. Hangauer, Jr.
Abstract: The application pertains to methods of treating and/or preventing actinic keratosis, comprising administering a therapeutically effective amount of KX-01, to a subject in need thereof.
Type:
Grant
Filed:
March 12, 2018
Date of Patent:
April 14, 2020
Assignee:
Athenex, Inc.
Inventors:
Min-Fun Rudolf Kwan, Johnson Yiu-Nam Lau, E. Douglas Kramer, David Lawrence Cutler, Jane Fang
Abstract: The present application is directed to biaryl piperidine amide compounds, or pharmaceutically acceptable salts, solvates, and prodrugs thereof, and methods of use thereof.
Type:
Grant
Filed:
March 15, 2018
Date of Patent:
October 22, 2019
Assignee:
Athenex, Inc.
Inventors:
Michael P. Smolinski, Sameer Urgaonkar, James Lindsay Clements, David G. Hangauer, Jr.
Abstract: The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl) pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. The invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention. The present invention also provides a novel polymorph of the mesylate salt of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide (Form A), characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well as a unique crystalline structure.
Type:
Grant
Filed:
December 21, 2016
Date of Patent:
June 18, 2019
Assignee:
Athenex, Inc.
Inventors:
David G. Hangauer, Jr., Debasis Patra, Jeremy A. Cody, Grant J. Palmer, Paul K. Isbester, Jonathon Salsbury
Abstract: The application relates to biaryl compounds, pharmaceutical compositions comprising the compounds, and methods of use the compounds for treating cell proliferation disorders.
Type:
Grant
Filed:
August 14, 2017
Date of Patent:
February 26, 2019
Assignee:
Athenex, Inc.
Inventors:
Michael P. Smolinski, Nader N. Nasief Abdel-Sayed, David G. Hangauer, Jr.
Abstract: The invention relates to compounds of formula IB and methods for modulating one or more components of a kinase cascade using these compounds.
Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase cascade. The invention also relates to substantially pure compound 1 and substantially pure compound 1 salt (e.g., compound 1 hydrochloride salt and compound 1 benzenesulfonate salt). The invention further relates to methods of preparing substantially pure compound 1 and compound 1 salts.
Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase cascade. The invention also relates to substantially pure compound 1 and substantially pure compound 1 salt (e.g., compound 1 hydrochloride salt and compound 1 benzenesulfonate salt). The invention further relates to methods of preparing substantially pure compound 1 and compound 1 salts.
Abstract: The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxyl)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. The invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxyl)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention. The present invention also provides a novel polymorph of the mesylate salt of 2-(5-(4-(2-morpholinoethoxyl)phenyl)pyridin-2-yl)-N-benzylacetamide (Form A), characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well as a unique crystalline structure.
Type:
Grant
Filed:
November 26, 2014
Date of Patent:
January 31, 2017
Assignee:
Athenex, Inc.
Inventors:
David G. Hangauer, Jr., Debasis Patra, Jeremy A. Cody, Grant J. Palmer, Paul K. Isbester, Jonathon Salsbury